All News

Siddhartha Yadav, MD, discusses real-world data demonstrating the mass underutilization of BRCA testing in patients with breast cancer.

For the first time, researchers identified sex-based differences in genetic expression of human pulmonary microvascular endothelial cells (HPMECs).

This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.

At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.

Gabriel Hortobagyi, MD, FACP, talks about the potential for further studies in HR-positive/HER2-negative breast cancer following the results of the NATALEE trial.

Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.

Patients with inflammatory bowel disease (IBD) receive additional evidence on the safety and efficacy of adalimumab biosimilar GP2017 treatment.

Treatment with blinatumomab or inotuzumab ozogamicin particularly confers higher total costs for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Cardiologists need skills in risk assessment, contraception counseling, and hypertension management for pregnant patients, according to Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.

A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.

Results showed that evobrutinib did not produce a more superior reduction in annualized relapse rates than teriflunomide, a previously approved disease-modifying agent.

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.

The FDA has approved a gene-editing therapy for sickle cell disease (SCD) for the first time.

This data represented the first-ever research presented at ACR on both fractures and calcium pyrophosphate deposition disease.

The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.

New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).

Mrinal M. Gounder, MD, a sarcoma oncologist at Memorial Sloan Kettering Cancer Center and lead investigator of the phase 3 DeFi trial of nirogacestat in desmoid tumors, discusses the drug's recent FDA approval and potential impacts on desmoid tumor treatment going forward.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.

Polycythemia vera (PV) therapy should aim to identify cardiovascular risk factors, according to one review.

Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.

The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.

Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.

Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.

Although the incidence of colorectal cancer (CRC) decreased in individuals older than 50 years, incidence of CRC increased in male individuals younger than 50 years.

Kelly-Anne Phillips, MD, shares new findings suggesting that hormonal contraceptive use can increase the risk for breast cancer in those with genetic variants of BRCA1 and BRCA2.

Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA) decreased.

The study’s investigators suggest the results in this patient population may indicate rises in clinically diagnosed viral infections from viruses other than SARS-CoV-2 following pandemic lockdown changes.